Q-omics provides the consensus-scored CRB1 profile across patient tissues and cancer cell-line models. CRB1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CRB1 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, CRB1 RNA expression shows 14,774 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KICH, and THYM as cancer lineages where CRB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRB1 survival associations across molecular data types. CRB1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (10) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRB1 RNA expression–survival associations across cancer types. High CRB1 expression shows unfavorable associations in UCEC, CESC, UVM and KIRP, but favorable associations in ACC and LGG. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for CRB1 RNA expression.
This table summarizes CRB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CRB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRB1 shows lower tumor expression in KICH, THCA, UCEC, COAD, LUSC and READ. The KICH box plot shows higher CRB1 RNA expression in normal versus tumor tissue (log2 FC = −0.217, t-test p < 0.001).
This table shows molecular features associated with CRB1 in patient tissues and cancer cell lines. In patient samples, CRB1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CRB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Myeloma.
